Advisory · Infectious Disease
Post-pandemic restructuring has created a valuation reset.
Ambrosia provides senior-led advisory for infectious disease licensing, M&A, and strategic partnerships — backed by a proprietary database of 100 verified infectious disease transactions.
Deal Landscape
What infectious disease transactions actually look like.
Verified Transactions
100
Median Upfront
$45M
Key Structure Insight
Antiviral and vaccine economics diverged sharply post-2023
Related Insights
Research relevant to infectious disease.
Stay Informed
Get new deal intelligence and transaction insights as we publish them.
No spam. Unsubscribe anytime.
Discuss your infectious disease transaction.
We’ll meet you at peer level — anywhere in the world.